These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28710915)

  • 1. Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.
    Ando M; Nagata K; Nihira K; Suzuki Y; Kanda Y; Adachi M; Kubota T; Kameyama N; Nakano M; Ando H; Yamano K; Ishii T; Nakai R; Nakamura K
    Transl Oncol; 2017 Oct; 10(5):707-718. PubMed ID: 28710915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.
    Akutagawa N; Nishikawa A; Iwasaki M; Fujimoto T; Teramoto M; Kitajima Y; Endo T; Shibuya M; Kudo R
    Jpn J Cancer Res; 2002 Jun; 93(6):644-51. PubMed ID: 12079512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
    Lin J; Spidel JL; Maddage CJ; Rybinski KA; Kennedy RP; Krauthauser CL; Park YC; Albone EF; Jacob S; Goserud MT; Martinez BP; Chao Q; Zhou Y; Nicolaides NC; Kline JB; Grasso L
    Cancer Biol Ther; 2013 Nov; 14(11):1032-8. PubMed ID: 24025360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer.
    Zeligs KP; Morelli MP; David JM; Neuman M; Hernandez L; Hewitt S; Ozaki M; Osei-Tutu A; Anderson D; Andresson T; Das S; Lack J; Abdelmaksoud A; Fantini M; Arlen PM; Tsang KY; Annunziata CM
    Front Oncol; 2020; 10():805. PubMed ID: 32637350
    [No Abstract]   [Full Text] [Related]  

  • 5. Host-derived antibody-dependent cytotoxic cells within murine tumors.
    Tracey DE; Silberman SL
    J Natl Cancer Inst; 1980 Jan; 64(1):111-8. PubMed ID: 6928035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow Cytometric Analysis of Ovarian Cancer Ascites: Response of Mesothelial Cells and Macrophages to Cancer.
    Hashimoto K; Honda K; Matsui H; Nagashima Y; Oda H
    Anticancer Res; 2016 Jul; 36(7):3579-84. PubMed ID: 27354626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction.
    Abiko K; Mandai M; Hamanishi J; Yoshioka Y; Matsumura N; Baba T; Yamaguchi K; Murakami R; Yamamoto A; Kharma B; Kosaka K; Konishi I
    Clin Cancer Res; 2013 Mar; 19(6):1363-74. PubMed ID: 23340297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
    Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
    Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent
    Ponath P; Menezes D; Pan C; Chen B; Oyasu M; Strachan D; LeBlanc H; Sun H; Wang XT; Rangan VS; Deshpande S; Cristea S; Park KS; Sage J; Cardarelli PM
    Clin Cancer Res; 2018 Oct; 24(20):5178-5189. PubMed ID: 30021910
    [No Abstract]   [Full Text] [Related]  

  • 10. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis.
    Wei X; Liu Y; Gong C; Ji T; Zhou X; Zhang T; Wan D; Xu S; Jin P; Yang X; Li X; Ma D; Yang Z; Gao Q
    Anticancer Agents Med Chem; 2017; 17(8):1093-1101. PubMed ID: 28002999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
    Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
    Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
    Smolle E; Taucher V; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
    Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
    Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant ascites determine the transmesothelial invasion of ovarian cancer cells.
    Mikuła-Pietrasik J; Uruski P; Szubert S; Szpurek D; Sajdak S; Tykarski A; Książek K
    Int J Biochem Cell Biol; 2017 Nov; 92():6-13. PubMed ID: 28888784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
    Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
    Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment.
    Arlt MJ; Novak-Hofer I; Gast D; Gschwend V; Moldenhauer G; Grünberg J; Honer M; Schubiger PA; Altevogt P; Krüger A
    Cancer Res; 2006 Jan; 66(2):936-43. PubMed ID: 16424028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.
    Lane D; Matte I; Rancourt C; Piché A
    J Ovarian Res; 2010 Jan; 3():1. PubMed ID: 20157422
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.